Abstract:DprE1 enzyme has emerged as one of the most vulnerable targets in M. tuberculosis and non‐covalent DprE1 inhibitors attracted considerable attention for the discovery of new anti‐tubercular agents. Among these compounds, TCA1, a non‐covalent DprE1 inhibitor has emerged as a potent drug candidate. In this regard, a series of TCA1 analogs were prepared through the pharmacophore hopping and evaluated for their anti‐tubercular activity against H37Ra. Among the compounds, Compounds 6 b and 6 f were emerged as lead compounds with MICs values of 4.0 and 8μg/mL respectively. Inhibitors of Decaprenylphosphoryl‐β‐D‐ribose 2′‐epimerase (DprE1) are being thoroughly explored as potential pharmacological entities for the development of new anti‐tubercular therapeutics. In this context, benzothiazole‐bearing compounds have emerged as potential non‐covalent DprE1 inhibitors active against mycobacterium tuberculosis. In view of the promising anti‐tubercular activity of benzothiazole based non‐covalent DprE1 inhibitor TCA1; a series of thirty small peptide conjugates of benzothiazole‐2‐carboxylic acid has been synthesized and evaluated for their anti‐tubercular activity against the M.tb H37Ra strain by broth microdilution assay. Among the compounds tested, compounds methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate and methyl (6‐methylbenzo[d]thiazole‐2‐carbonyl)tryptophylalaninate demonstrated potential anti‐tubercular activity with minimum inhibitory concentration (MIC) values of 4 and 8 μg/mL, respectively. These compounds were further identified to be mycobactericidal and are completely killing the microbes at 8‐16 μg/mL concentrations. Furthermore, the cytotoxicity study of most potent compound methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate illustrated no significant toxicity to the human cell line HepG2. Moreover, synthesised compounds were subject to molecular docking, ADME studies and MM‐GBSA calculations. In silico studies suggest that these compounds show strong interactions with key amino acids in the binding pocket of DprE1 (PDBID: 4KW5) with the most active conjugates residing well (with docking scores of −08.49 and −7.902 kcal/mol).

Exploring rhodanine linked enamine–carbohydrazide derivatives as mycobacterial carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and molecular docking studies

Exploration of isoxazole‐carboxylic acid methyl ester based 2‐substituted quinoline derivatives as promising antitubercular agents

Design, synthesis, and anti-mycobacterial evaluation of 1,8-naphthyridine-3-carbonitrile analogues

Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B

A multi-dimensional systems biology approach to elucidate the mechanism of action of Mycobacterium tuberculosis γ-carbonic anhydrase inhibitors

New Synergistic Benzoquinone Scaffolds as Inhibitors of Mycobacterial Cytochrome bc1 Complex to Treat Multi-Drug Resistant Tuberculosis

A cheminformatics and network pharmacology approach to elucidate the mechanism of action of Mycobacterium tuberculosis γ-carbonic anhydrase inhibitors

New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling

Benzothiadiazinone-1,1-Dioxide Carbonic Anhydrase Inhibitors Suppress the Growth of Drug-Resistant Mycobacterium tuberculosis Strains

Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies

Small Peptide Conjugates of Benzothiazole‐2‐Carboxylic Acids Targeting DprE1 Against Tuberculosis

Design and synthesis of Thieno[3, 2- b ]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase

Chemical synthesis and molecular modeling of novel substituted N-1,3-benzoxazol-2yl benzene sulfonamides as inhibitors of inhA enzyme and Mycobacterium tuberculosis growth

Benzenesulfonohydrazide-tethered non-fused and fused heterocycles as potential anti-mycobacterial agents targeting enoyl acyl carrier protein reductase (InhA) with antibiofilm activity

Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis

Design, synthesis and characterization of ethyl 3‐benzoyl‐7‐morpholinoindolizine‐1‐carboxylate as anti‐tubercular agents: In silico screening for possible target identification

N-Acyl phenothiazines as mycobacterial ATP synthase inhibitors: Rational design, synthesis and in vitro evaluation against drug sensitive, RR and MDR-TB

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

Mechanistic modeling of β-carbonic anhydrase inhibitors using integrated systems biology and the QSAR approach

Benzo[d]Thiazole-2-Carboxamides/Carbanilides as New Anti-TB Chemotypes Inhibiting the Mycobacterial ATP-Phosphoribosyl Transferase (HisG)

Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents